- Home
- SARO vs LEGN Comparison
SARO vs LEGN Comparison
Compare SARO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SARO
- LEGN
- Stock Information
- Founded
- SARO 1911
- LEGN 2014
- Country
- SARO United States
- LEGN United States
- Employees
- SARO N/A
- LEGN N/A
- Industry
- SARO
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- SARO
- LEGN Health Care
- Exchange
- SARO NYSE
- LEGN Nasdaq
- Market Cap
- SARO 9.3B
- LEGN 7.0B
- IPO Year
- SARO 2024
- LEGN 2020
- Fundamental
- Price
- SARO $28.37
- LEGN $28.33
- Analyst Decision
- SARO Buy
- LEGN Strong Buy
- Analyst Count
- SARO 8
- LEGN 13
- Target Price
- SARO $34.75
- LEGN $75.67
- AVG Volume (30 Days)
- SARO 1.8M
- LEGN 1.6M
- Earning Date
- SARO 05-12-2025
- LEGN 05-13-2025
- Dividend Yield
- SARO N/A
- LEGN N/A
- EPS Growth
- SARO N/A
- LEGN N/A
- EPS
- SARO 0.23
- LEGN N/A
- Revenue
- SARO $5,437,026,000.00
- LEGN $728,303,000.00
- Revenue This Year
- SARO $15.54
- LEGN $64.21
- Revenue Next Year
- SARO $11.37
- LEGN $53.69
- P/E Ratio
- SARO $120.26
- LEGN N/A
- Revenue Growth
- SARO 17.03
- LEGN 112.46
- 52 Week Low
- SARO $21.31
- LEGN $27.34
- 52 Week High
- SARO $34.38
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- SARO N/A
- LEGN 36.81
- Support Level
- SARO N/A
- LEGN $27.34
- Resistance Level
- SARO N/A
- LEGN $33.30
- Average True Range (ATR)
- SARO 0.00
- LEGN 1.91
- MACD
- SARO 0.00
- LEGN -0.30
- Stochastic Oscillator
- SARO 0.00
- LEGN 13.51
About SARO STANDARDAERO INC.
StandardAero Inc is a provider of aftermarket services for fixed and rotary wing aircraft gas turbine engines and auxiliary power units (APUs) to the commercial, business, and military aircraft markets. It also provides aftermarket and upgrade services for business aviation and helicopter airframes and avionics. It operates in two segments Engine Services and Component Repair Services. The group generates the majority of its revenue from the Engine Services segment which provides engine and airframe maintenance, repair, overhaul, and related services to customers in the Commercial Aerospace, Military & Helicopter, and Business Aviation end markets.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.